Mentor Corporation (MNTR) Capital Chairman Highlights $0.91/Share Non-GAAP Gains from Cancer Portfolio Appreciation
1/25/2010 12:13:07 PM
SAN DIEGO--(BUSINESS WIRE)--Mentor Capital, Inc. (Pink Sheets:MNTR) Chairman, in his 2009 Letter to Shareholders, outlined $0.91/sh gains. On a mark-to-market basis Mentor Capital projected earnings per basic outstanding share for 2009 would be approximately 91 cents per share. On a fully diluted basis, Company mark-to-market earnings would be approximately 29 cents per average share equivalent for the year. The majority of Mentor Capital mark-to-market gains, used internally to judge management performance, are in the appreciation of cancer immunotherapy stock holdings. On a GAAP basis, these gains will not be recognized until later. Not counting these portfolio gains, the GAAP earnings per basic share, on a more precise but still not audited basis, would be an 18 cent loss, generally reflecting Company operating expenses.
comments powered by